Base de dados : MEDLINE
Pesquisa : D27.505.696.875.360.276 [Categoria DeCS]
Referências encontradas : 5769 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 577 ir para página                         

  1 / 5769 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29424969
[Au] Autor:Martínez-Ramírez EA; Villarreal-Ríos E; Vargas-Daza ER; Galicia-Rodríguez L; Martínez-González L
[Ti] Título:[Cost of family planning care in 10-19 years old teenagers].
[Ti] Título:Costo de atención por servicios de planificación familiar a adolescentes de 10-19 años..
[So] Source:Ginecol Obstet Mex;84(9):551-6, 2016 Sep.
[Is] ISSN:0300-9041
[Cp] País de publicação:Mexico
[La] Idioma:spa
[Ab] Resumo:Objetives: To identify the costs of family planning care in adolescents. Material and methods: Longitudinal study of the cost of care for family planning carried out in 2015 in a group of individuals with age limits of 10 and 19 years in a unit first level of health care in the state of Queretaro, Mexico. The profile of use of family planning (FP) was created for the teen was performed services through counseling, provision of contraception and review of intrauterine device (IUD) in a year; cost projections for the population of adolescents and different coverage scenarios between 5 and 100% were made. Results: The average annual cost was 228.84 Mexican pesos. Ideally the identified cost was 2,708.94 pesos. The projection with 20 % coverage was 207,251,330 pesos. The average annual family planning consultations was 0.9. The most commonly used method was with medroxyprogesterone-estradiol at doses of 25 and 5 mg. Conclusion: The cost of planning in adolescents is low, taking into account the costs that the care of high-risk pregnancies and associated comorbidities.
[Mh] Termos MeSH primário: Anticoncepção/economia
Anticoncepcionais Femininos/economia
Serviços de Planejamento Familiar/economia
Dispositivos Intrauterinos/economia
[Mh] Termos MeSH secundário: Adolescente
Criança
Anticoncepção/métodos
Anticoncepcionais Femininos/administração & dosagem
Combinação de Medicamentos
Estradiol/administração & dosagem
Estradiol/economia
Feminino
Seres Humanos
Estudos Longitudinais
Masculino
Acetato de Medroxiprogesterona/administração & dosagem
Acetato de Medroxiprogesterona/economia
México
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Drug Combinations); 4TI98Z838E (Estradiol); C2QI4IOI2G (Medroxyprogesterone Acetate)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE


  2 / 5769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29234797
[Au] Autor:Gomez AM
[Ad] Endereço:Sexual Health and Reproductive Equity Program, School of Social Welfare, University of California, Berkeley.
[Ti] Título:Availability of Pharmacist-Prescribed Contraception in California, 2017.
[So] Source:JAMA;318(22):2253-2254, 2017 Dec 12.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticoncepcionais Femininos
Prescrições de Medicamentos/estatística & dados numéricos
Farmácias/estatística & dados numéricos
[Mh] Termos MeSH secundário: California
Seres Humanos
Farmacêuticos
Honorários por Prescrição de Medicamentos/estatística & dados numéricos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptive Agents, Female)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.15674


  3 / 5769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29172413
[Au] Autor:Deshmukh P; Antell K; Brown EJ
[Ti] Título:Contraception Update: Progestin-Only Implants and Injections.
[So] Source:FP Essent;462:25-29, 2017 Nov.
[Is] ISSN:2159-3000
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Progestin-only contraception is a popular method of birth control in the United States and worldwide. Progestin-only implants and injections allow patients access to long-term contraception with simple options for reversal or removal. The implant is one of the most effective forms of contraception and there are few contraindications. Manufacturer-led training is required to become certified in insertion and removal. The most common adverse effect of the implant is a change in menstrual bleeding patterns. Little evidence has shown weight gain or decreased bone mineral density with use. The depot medroxyprogesterone acetate (DMPA) injection is used widely and is effective. Adverse effects that may limit use include changes in bleeding patterns and bone mineral density loss, which is reversible after discontinuation. The risk of weight gain with DMPA is greatest in obese adolescents and black patients. There is no significantly increased risk of cancer with either method. Both are safe for use in the postpartum period, during breastfeeding, and immediately after abortion.
[Mh] Termos MeSH primário: Anticoncepcionais Femininos/uso terapêutico
Implantes de Medicamento
Serviços de Planejamento Familiar
Medicina de Família e Comunidade
Acetato de Medroxiprogesterona/uso terapêutico
Progestinas
[Mh] Termos MeSH secundário: Anticoncepcionais Femininos/administração & dosagem
Anticoncepcionais Femininos/efeitos adversos
Remoção de Dispositivo
Interações Medicamentosas
Feminino
Seres Humanos
Injeções
Acetato de Medroxiprogesterona/administração & dosagem
Acetato de Medroxiprogesterona/efeitos adversos
Ganho de Peso
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Drug Implants); 0 (Progestins); C2QI4IOI2G (Medroxyprogesterone Acetate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  4 / 5769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29369858
[Au] Autor:Zolot J
[Ad] Endereço:Joan Zolot, PA.
[Ti] Título:Updated Recommendations for Women's Health.
[So] Source:Am J Nurs;118(2):13, 2018 02.
[Is] ISSN:1538-7488
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:ACOG addresses important issues in contraception and cesarean delivery.
[Mh] Termos MeSH primário: Saúde da Mulher
[Mh] Termos MeSH secundário: Anticoncepcionais Femininos
Disbiose/terapia
Feminino
Seres Humanos
Recém-Nascido
Dispositivos Intrauterinos
Guias de Prática Clínica como Assunto
Gravidez
Vagina/microbiologia
Nascimento Vaginal Após Cesárea
[Pt] Tipo de publicação:NEWS
[Nm] Nome de substância:
0 (Contraceptive Agents, Female)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM; N
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1097/01.NAJ.0000530230.38156.fa


  5 / 5769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310336
[Au] Autor:Park JU; Bae HS; Lee SM; Bae J; Park JW
[Ad] Endereço:Department of Plastic and Reconstructive Surgery.
[Ti] Título:Removal of a subdermal contraceptive implant (Implanon NXT) that migrated to the axilla by C-arm guidance: A case report and review of the literature.
[So] Source:Medicine (Baltimore);96(48):e8627, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: To report the distant migration of a subdermal contraceptive implant and to suggest that C arm-guided technique is one of the feasible options for removal of the device migrated to the axilla. PATIENT CONCERNS: A 41-year-old multipara with tingling sensation in the left axilla was referred for removal of an Implanon NXT which could not be palpated by physical examination or detected by ultrasound scanning. Finally, the device was detected by computed tomography and found migrating to the left axilla. DIAGNOSIS: Migration of Implanon NXT to the left axilla abutting the brachial plexus. INTERVENTIONS: The device was removed by C arm-guiding. OUTCOMES: The patient went home without any procedure-related complications. LESSONS: The incidence of distant migration of a subdermal implant is possible and should be checked up regularly. If the device cannot be palpated or detected by ultrasound at the original implanting site, this should be concerned. Since the single-rod subdermal implant is radiopaque, it can be detected by roentgenography. In this case the distant migration was detected in the axilla, therefore using C arm-guided technique is feasible for the removal of the migrating device. After reviewing the literature, totally 10 cases of distant migration were reported including 2 cases of migration which were advanced further to the pulmonary artery as an embolization.
[Mh] Termos MeSH primário: Anticoncepcionais Femininos
Remoção de Dispositivo
Implantes de Medicamento
Migração de Corpo Estranho/diagnóstico por imagem
Migração de Corpo Estranho/cirurgia
Radiografia Intervencionista
[Mh] Termos MeSH secundário: Adulto
Axila/diagnóstico por imagem
Axila/cirurgia
Desogestrel
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Drug Implants); 304GTH6RNH (etonogestrel); 81K9V7M3A3 (Desogestrel)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008627


  6 / 5769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773713
[Au] Autor:Karpilow QC; Thomas AT
[Ad] Endereço:Child Trends, Bethesda, MD.
[Ti] Título:Reassessing the importance of long-acting contraception.
[So] Source:Am J Obstet Gynecol;216(2):148.e1-148.e14, 2017 Feb.
[Is] ISSN:1097-6868
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Several recent studies have highlighted the need for greater use of long-acting contraception. The most influential of these studies is the Contraceptive CHOICE Project, which was credited with substantially reducing participants' pregnancy risk by increasing their use of long-acting methods such as intrauterine devices and subdermal implants. However, because participants' rates of nonuse and condom use fell to zero at the outset of the intervention, it is possible that sizable pregnancy reductions could still have been achieved if enrollees had chosen shorter-acting, female-controlled methods such as oral contraception. OBJECTIVE: The objective of the study was to estimate the proportion of the CHOICE Project's fertility impacts that could have been achieved without any increase in long-acting method use. STUDY DESIGN: The FamilyScape 3.0 microsimulation model was used to estimate CHOICE's impact on pregnancy risk and to simulate the counterfactual effect of moving all nonusers and condom users onto shorter-acting, female-controlled methods. FamilyScape models the sexual and contraceptive behaviors of women in the United States between 2006 and 2010, which is the period when CHOICE was implemented. RESULTS: Nearly three quarters of the CHOICE intervention's effects on pregnancy risk could have been achieved if participants had chosen shorter-acting, female-controlled methods over long-acting methods. CONCLUSION: Prioritizing the adoption of long-acting contraception may not be the most advisable strategy for reducing unintended pregnancy. The most impactful interventions will likely be those that increase the use of female-controlled methods, long-acting or otherwise.
[Mh] Termos MeSH primário: Comportamento Contraceptivo/estatística & dados numéricos
Anticoncepção/métodos
Anticoncepcionais Femininos/uso terapêutico
Dispositivos Intrauterinos/utilização
[Mh] Termos MeSH secundário: Simulação por Computador
Anticoncepcionais Orais/uso terapêutico
Preparações de Ação Retardada
Implantes de Medicamento
Feminino
Seres Humanos
Modelos Teóricos
Gravidez
Gravidez não Planejada
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Contraceptives, Oral); 0 (Delayed-Action Preparations); 0 (Drug Implants)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:180112
[Lr] Data última revisão:
180112
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161107
[St] Status:MEDLINE


  7 / 5769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29064972
[Au] Autor:Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group
[Ti] Título:Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices.
[So] Source:Obstet Gynecol;130(5):e251-e269, 2017 11.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARC), are the most effective reversible contraceptive methods. The major advantage of LARC compared with other reversible contraceptive methods is that they do not require ongoing effort on the part of the patient for long-term and effective use. In addition, after the device is removed, the return of fertility is rapid (1, 2). The purpose of this Practice Bulletin is to provide information for appropriate patient selection and evidence-based recommendations for LARC initiation and management. The management of clinical challenges associated with LARC use is beyond the scope of this document and is addressed in Committee Opinion No. 672, Clinical Challenges of Long-Acting Reversible Contraceptive Methods (3).
[Mh] Termos MeSH primário: Anticoncepcionais Femininos/administração & dosagem
Implantes de Medicamento
Dispositivos Intrauterinos
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Drug Implants)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002400


  8 / 5769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29064966
[Ti] Título:Practice Bulletin No. 186 Summary: Long-Acting Reversible Contraception: Implants and Intrauterine Devices.
[So] Source:Obstet Gynecol;130(5):1173-1175, 2017 Nov.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARC), are the most effective reversible contraceptive methods. The major advantage of LARC compared with other reversible contraceptive methods is that they do not require ongoing effort on the part of the patient for long-term and effective use. In addition, after the device is removed, the return of fertility is rapid (1, 2). The purpose of this Practice Bulletin is to provide information for appropriate patient selection and evidence-based recommendations for LARC initiation and management. The management of clinical challenges associated with LARC use is beyond the scope of this document and is addressed in Committee Opinion No. 672, Clinical Challenges of Long-Acting Reversible Contraceptive Methods (3).
[Mh] Termos MeSH primário: Anticoncepcionais Femininos
Implantes de Medicamento
Dispositivos Intrauterinos
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Drug Implants)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002394


  9 / 5769 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29027769
[Au] Autor:Internal Revenue Service, Department of the Treasurey.; Employee Benefits Security Administration, Department of Labor.; Centers for Medicare & Medicaid Services, Department of Health and Human Services.
[Ti] Título:Moral Exemptions and Accommodations for Coverage of Certain Preventive Services Under the Affordable Care Act. Interim final rules with request for comments.
[So] Source:Fed Regist;82(197):47838-62, 2017 Oct 13.
[Is] ISSN:0097-6326
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The United States has a long history of providing conscience protections in the regulation of health care for entities and individuals with objections based on religious beliefs or moral convictions. These interim final rules expand exemptions to protect moral convictions for certain entities and individuals whose health plans are subject to a mandate of contraceptive coverage through guidance issued pursuant to the Patient Protection and Affordable Care Act. These rules do not alter the discretion of the Health Resources and Services Administration, a component of the United States Department of Health and Human Services, to maintain the guidelines requiring contraceptive coverage where no regulatorily recognized objection exists. These rules also provide certain morally objecting entities access to the voluntary "accommodation" process regarding such coverage. These rules do not alter multiple other Federal programs that provide free or subsidized contraceptives for women at risk of unintended pregnancy.
[Mh] Termos MeSH primário: Anticoncepção/economia
Anticoncepção/ética
Anticoncepcionais Femininos/economia
Cobertura do Seguro/economia
Cobertura do Seguro/legislação & jurisprudência
Princípios Morais
Patient Protection and Affordable Care Act/economia
Patient Protection and Affordable Care Act/legislação & jurisprudência
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Gravidez
Religião
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptive Agents, Female)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:171015
[St] Status:MEDLINE


  10 / 5769 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29027768
[Au] Autor:Internal Revenue Services, Department of the Treasury.; Employee Benefits Security Administration, Department of Labor.; Centers for Medicare & Medicaid Services, Department of Health and Human Services.
[Ti] Título:Religious Exemptions and Accommodations for Coverage of Certain Preventive Services Under the Affordable Care Act. Interim final rules with request for comments.
[So] Source:Fed Regist;82(197):47792-835, 2017 Oct 13.
[Is] ISSN:0097-6326
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The United States has a long history of providing conscience protections in the regulation of health care for entities and individuals with objections based on religious beliefs and moral convictions. These interim final rules expand exemptions to protect religious beliefs for certain entities and individuals whose health plans are subject to a mandate of contraceptive coverage through guidance issued pursuant to the Patient Protection and Affordable Care Act. These rules do not alter the discretion of the Health Resources and Services Administration (HRSA), a component of the United States Department of Health and Human Services (HHS), to maintain the guidelines requiring contraceptive coverage where no regulatorily recognized objection exists. These rules also leave the "accommodation" process in place as an optional process for certain exempt entities that wish to use it voluntarily. These rules do not alter multiple other Federal programs that provide free or subsidized contraceptives for women at risk of unintended pregnancy.
[Mh] Termos MeSH primário: Anticoncepção/economia
Anticoncepcionais Femininos/economia
Cobertura do Seguro/economia
Cobertura do Seguro/legislação & jurisprudência
Patient Protection and Affordable Care Act/economia
Patient Protection and Affordable Care Act/legislação & jurisprudência
Religião
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Gravidez
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptive Agents, Female)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:171015
[St] Status:MEDLINE



página 1 de 577 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde